HORSHAM, Pa., April 22, 2026

Johnson & Johnson has reported compelling long-term Phase 3 data demonstrating that IMAAVY® (nipocalimab-aahu) delivers sustained disease control and meaningful clinical improvements in patients with generalized myasthenia gravis (gMG) over a period of more than two years (120 weeks). The findings, presented at the American Academy of Neurology (AAN) 2026 Meeting, reinforce the therapy’s durability, safety profile, and ability to improve patient quality of life, positioning IMAAVY as a key treatment option in the evolving landscape of autoimmune neuromuscular disorders.

Sustained Efficacy and Symptom Control Over Two Years

The Phase 3 Vivacity-MG3 study and its ongoing open-label extension (OLE) demonstrated that patients treated with IMAAVY experienced consistent and sustained improvements in disease severity and daily functioning. Clinical outcomes showed significant reductions in MG-ADL and QMG scores, key measures of symptom burden and muscle strength, indicating long-term stabilization of disease activity.

Notably, over half of patients achieved minimal symptom expression (MSE), with approximately 32% maintaining sustained MSE for at least eight weeks, a critical indicator of low disease impact on daily life. Additionally, patients experienced a greater than 64% reduction in total immunoglobulin G (IgG) levels, directly targeting the underlying autoimmune drivers of the disease. These results highlight the therapy’s ability to provide durable disease control, which is essential for reducing exacerbations and improving long-term outcomes in gMG patients.

Improved Quality of Life and Reduced Treatment Burden

Advertisement

cGxPJobs Banner

A post-hoc analysis of the study further demonstrated that patients achieving sustained minimal symptom expression experienced significantly greater improvements in quality of life, as measured by validated patient-reported outcomes. Patients receiving IMAAVY in combination with standard of care were four times more likely to achieve sustained symptom control compared to placebo, underscoring its clinical superiority in managing chronic autoimmune conditions.

Importantly, the therapy also enabled a reduction in corticosteroid use, with 57% of patients achieving low-dose steroid levels, thereby minimizing long-term side effects associated with steroid dependency. These findings emphasize the patient-centric benefits of IMAAVY, including improved daily functioning, reduced treatment burden, and enhanced overall well-being, which are critical considerations in chronic disease management.

Advancing Innovation in Autoimmune and Rare Diseases

IMAAVY is an FcRn-blocking immunotherapy designed to selectively reduce pathogenic IgG antibodies while preserving essential immune functions, representing a next-generation approach to treating autoimmune diseases. The therapy has received multiple regulatory designations, including Fast Track, Breakthrough Therapy, and Orphan Drug status from global regulatory authorities, reflecting its potential to address significant unmet medical needs.

Beyond gMG, nipocalimab is being investigated across a broad range of autoimmune and rare conditions, including rheumatologic diseases and maternal-fetal disorders, highlighting its versatility and long-term therapeutic potential. With ongoing studies such as the EPIC trial, which compares IMAAVY to other FcRn inhibitors, Johnson & Johnson continues to strengthen its leadership in innovative immunology and neuroscience therapies. These advancements signal a new era of precision medicine, where targeted therapies can deliver sustained efficacy and improved quality of life for patients with complex autoimmune diseases.

Source: Johnson & Johnson press release